← board
TBPH
Theravance Biopharmadistress 0/10 · well-funded / low risk$16.86+0%today-19% from 52w high
Lead: symptomatic neurogenic orthostatic hypotension due to multiple system atrophy
Revenue
$18M
Liquidity
$288M
Runway
—
Shares 1y
+2%
Price & events
-18.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.3%
1D
-0.7%
1W
-0.7%
1M
+3.3%
3M
-16.7%
6M
+49.2%
1Y
+67.2%
2Y
+24.2%
5Y
-3.9%
All
Overview
- Market Cap
- $868.93M
- Volume
- 52.88K
- 52 Week Range
- $10.90 – $20.74
- Total Shares
- 51.55M
- Float Shares
- 24.15M
- Short %
- 13.88%
- % Held by Insiders
- 4.68%
- % Held by Institutions
- 98.22%
- RVOL
- 0.07x
- Beta
- 0.17
Pipeline stages · 1 programs
Ampreloxetine, Placebo
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-01 | Phase 3 | Ampreloxetine, Placeboorphan | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 102 | active not recruiting |
Catalyst news & presentations · 11
- 2026-08-12earningsEarningsEarnings releaseyahoo
- 2026-06-28partnershipampreloxetine · Merger with Zymeworks including CVR for ampreloxetine monetizationSEC 8-K
- Q1 2026readoutPhase 3ampreloxetine · Topline results from Phase 3 CYPRESS studySEC 8-K
- 2026-03-27partnershipYUPELRI · Settlement agreement with Mankind Pharma resolving patent litigation, granting royalty-free license for generic version on or after April 23, 2039SEC 8-K
- 2026-03-03trial discontinuedampreloxetine · Company decided to wind down ampreloxetine program due to failed studySEC 8-K
- Q3 2025enrollment completesecondaryPhase 3ampreloxetine · Completed enrollment in Phase 3 CYPRESS trialSEC 8-K
- 2025-08-15partnershipYUPELRI · Settlement agreement with Cipla granting license for generic revefenacin on April 23, 2039.SEC 8-K
- Mid-2025enrollment completesecondaryPhase 3amprexetine · Last patient enrolled in registrational Phase 3 CYPRESS studySEC 8-K
- 2025-05-30partnershipTrelegy Ellipta · Sold remaining royalty interest in Trelegy Ellipta to GSK for $225MSEC 8-K
- 2024-09-18partnershipYUPELRI (revefenacin) · Settlement with Qilu resolves patent litigation; grants royalty-free license for generic launch on April 23, 2039, subject to FTC review.SEC 8-K
- June 2024regulatory submissionFiled (NDA/BLA)YUPELRI · NDA submitted in China for COPDSEC 8-K
Approved drugs (1)
- VIBATIVTELAVANCIN2013 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $18 (+5% upside) · 3 analysts
- 2026-07-07HC Wainwright & Co.Buy → Neutral
- 2026-06-29Jones TradingBuy → Hold
- 2026-06-29BTIGBuy → Neutral
- 2026-04-07B. Riley SecuritiesNeutral
- 2026-03-23TD CowenHold
- 2026-03-20BTIGBuy
Competitors — symptomatic neurogenic orthostatic hypotension due to multiple system atrophy
- none identified
Recent news
- 2026-07-21Liquidity Mapping Around (TBPH) Price Events - Stock Traders Daily
- 2026-07-16Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 - GlobeNewswire
- 2026-07-16Zymeworks Won’t Host Q2 Call Amid Proposed Theravance Deal - Stock Titan
- 2026-07-10Theravance Biopharma Inc (TBPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
- 2026-07-10Liquidity Mapping Around (TBPH) Price Events - Stock Traders Daily
- 2026-07-10Theravance Biopharma (TBPH) Hovers Near Support Amidst Quiet Trading Session - Protective Put - dars.gov.et
- 2026-07-09Are TBPH, IRDM, LCII, PATK Obtaining Fair Deals for their Shareholders? - AOL.com
- 2026-07-09Are TBPH, IRDM, LCII, PATK Obtaining Fair Deals for their Shareholders? - PR Newswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.